New Guide: Medication-Assisted Treatment for Alcohol Use Disorder

Having trouble viewing this email? View it in your browser. Bookmark and Share
SAMHSA

New Guidance on Medication-Assisted Treatment for Alcohol Use Disorder

Brief Document

SAMHSA has released a new guide for expanding the use of medication in clinical practice for the treatment of alcohol use disorder: Medication for the Treatment of Alcohol Use Disorder—A Brief Guide.

The guide was created in partnership with the National

Institute on Alcohol Abuse and Alcoholism by convening a panel composed of experts in research, clinical care, medical education, and public policy. It summarizes information on the four medications approved by the U.S. Food and Drug Administration (FDA) to treat alcohol use disorder, prevent relapse to alcohol use, or both. The FDA-approved medications are disulfiram, oral naltrexone, extended-release injectable naltrexone, and acamprosate.

The new guide addresses six key topics:

  • Considering medications based on FDA-approved indications and a patient's unique needs and circumstances
  • Screening a patient for risky alcohol use
  • Assessing need for medication-assisted treatment
  • Developing a treatment plan and selecting a medication
  • Treating a patient with co-occurring disorders
  • Monitoring a patient's progress.

Download the Brief Guide

Like SAMHSA on Facebook   Follow SAMHSA on Twitter   Subscribe to SAMHSA's YouTube Channel   Visit the SAMHSA Dialogue Blog

Publications  |  Update My Profile  |  Unsubscribe  |  Contact Us

Substance Abuse & Mental Health Services Administration
1 Choke Cherry Road  |  Rockville, MD 20857
1-877-SAMHSA-7 (1-877-726-4727)  |  www.samhsa.gov  |  Privacy

United States Department of Health and Human Services

SAMHSA is a public health agency within the U.S. Department of Health and Human Services. Its mission is to reduce the impact of substance abuse and mental illness on America's communities.

This email was delivered to Email Address.

Forwarded this by a friend? Subscribe and join over 200,000 people receiving the latest on substance use and mental health.